No Binding to peptidilicos inhibitors of vla-4 dependent cells useful in the treatment of autoimmune and inflammatory diseases, respiratory

摘要

Structure refers to non Peptide compounds of formula (1.0.0), a is aryl, heteroaryl, a1nhconha2, a1nhcooa2, among others; A1 and A2 are h, aryl, heteroaryl, heterocycle; b is a Group (1.1.(2) 1.1.6), among others; and it is a Link, or CH = CH, A1A is cr1r1a; when H is a monovalent Substituent R1 and R1 when A1A is a Link, is a divalent Substituent; X is o, S (0) Q, and is nr14; SO2, co, CS,CHRA; M is 0 - 2; n is 1 - 2, p is 1 - 2; Q is 0 - 2; R is tetrazolilo, CO (CH2) kcoor5, conhso2r5, so2nr14r15, co nhso2r6 Group (3.0.0); K is 0 - 2; R2 and R3 are h, alkyl - C1 alquenilo C2 - C6, C4, among others.A Preferred Compound is acid, 3 - [2 - (3 - methyl - 1 - {2 - [4 - (3 - o-tolyl - ureido) phenyl] - acetylamino - Butyl) - oxazole 4,5-dihydro - - 5 - yl] - propionic acid, among others.It also relates to a Pharmaceutical composition comprising Plus theophylline, sulfasalazine, aminosalicylates, Cyclosporin, Rapamycin, clofosfamida, methotrexate, interferons.Compound 1 is an inhibitor of the binding of very late antigen (4 Integrin vla-4 Integrin), of leukocytes (o4u00df1) (cd49d / CD29) to proteins and cell adhesion molecule-1 (vcam-1)The Domain hepii / IIICS region (s-1) of Fibronectin and osteopontin, inhibit cell adhesion by what may be useful in the treatment of autoimmune and inflammatory diseases, respiratory